How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells (Ca2+)

July 24, 2023 updated by: Barbara Lawrenz, ART Fertility Clinics LLC

To Investigate How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ (Intracellular Calcium) Signals in Uterine Epithelial Cells

To develop a deeper understanding of endometrial-embryo crosstalk through basic research, uncover therapeutic targets and to improve reproductive outcome.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

Pregnancy is a complex and highly coordinated physiological process that involves implantation of a hatched blastocyst into a decidualizing endometrium. The main purpose of implantation is to ensure that the blastocyst firmly anchors into the decidual stroma, which allows further development by enabling placentation. Although a multitude of cellular events and molecular pathways involved in embryo-uterine crosstalk have been identified in mouse models, a comprehensive understanding of human embryo-uterine interaction is still missing. Our work indicates that endometrial epithelial Ca2+ signalling in response to serine proteases released by human embryos plays an important role in maternal recognition and selection of the conceptus at implantation. Previous studies have demonstrated that trophoblast spheroids can elevate [Ca2+]i in human uterine epithelial cell line (Ishikawa) by activating Ca2+ entry via mechano-sensitive Ca2+ permeable channels leading to the induction of epithelial adhesiveness. However, the mechanism(s) mediating the protease-induced [Ca2+]i transients in human uterine epithelium have not been studied to date. Investigators hypothesise that Na+ entry into the intravillous space via trypsin-activated ENaC will depolarise the cellular membrane and increase [Na+]v sufficiently high to reverse the sodium/calcium exchanger providing means for Ca2+ entry into the intravillous space. Ca2+ diffusion from the microvilli into the bulk cytoplasm will increase [Ca2+]i and, in parallel with SOCE, act as a source for re-filling of the ER. Increased [Ca2+]i will also activate the BK channels leading to repolarisation and termination of Ca2+ entry via the NCX.

By using spent medium from embryos, which will undergo pre-implantation genetic testing, it will become possible to determine, whether the above mentioned mechanisms are influenced by the ploidy status of the embryo.

Study Type

Observational

Enrollment (Actual)

81

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 36 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Arab ethnicity, with primary / secondary infertility, who undergo an ICSI treatment with preimplantation genetic testing for aneuploidies.

Description

Inclusion Criteria:

  • Couples with primary / secondary infertility who are planned to undergo ICSI treatment with PGT-A
  • Age of each partner above 18 years

Exclusion Criteria:

  • Couples with consanguinity (couple who is 1st or 2nd degree cousins)
  • Couples in whom the female partner has a history of:
  • Chemotherapy or radiation which impacts the ovarian reserve
  • Surgery at the ovaries / adnex region
  • Endometriosis
  • Couples in whom the male partner has a history of:
  • Chemotherapy / Radiation which impacts the semen result
  • Surgery at the testicles
  • Vasectomy
  • Surgery for reversal of vasectomy
  • Semen obtained by fine needle aspiration (FNA) or Testicular sperm extraction (TESE)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
DEG n1: euploid medium
culture media derived from euploid embryos
Exposure to culture media
DEG n2: aneuploid medium
culture media derived from aneuploid embryos
Exposure to culture media
DEG n3: medium arrested embryos
culture media derived from arrested embryos
Exposure to culture media
DEG n4: control culture medium
pure culture media without contact to embryos
Exposure to culture media

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in markers of protein
Time Frame: 1 day
Change in markers of protein (PAR2, (p) and SGK1, NFkB, ORAI1-3 and STIM1-2 and COX2) using Western blotting
1 day
Change in peak and slope levels of intracellular calcium
Time Frame: 1 day
Change in peak and slope levels of intracellular calcium
1 day
Change in morphohology of cells after incubation with embryo media
Time Frame: 1 day
Change in morphohology of cells after incubation with embryo media
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Performance of ICSI
Time Frame: 1 day
Defined on day 0 as the number of injected oocytes/number of COCs assigned to the ICSI group
1 day
Embryo quality on day 3
Time Frame: 1 day
Defined by the number of blastomeres and their division pattern, fragmentation, presence of compaction, vacuoles, granulation and nuclei
1 day
Embryo quality on day 5 (Gardner and Schoolcraft,1999)
Time Frame: 1 day

Gardner and Schoolcraft,1999) defined by:

  • The expansion stage of the blastocyst
  • Quality of the ICM and TE
  • Day on which the biopsy is performed (day 5,6 or 7)
  • Pregnancy outcomes (miscarriages/ectopic pregnancy/neonatal outcome)
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Barbara Lawrenz, PhD, ART Fertility Clinics LLC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2021

Primary Completion (Actual)

November 16, 2022

Study Completion (Estimated)

January 15, 2024

Study Registration Dates

First Submitted

April 26, 2021

First Submitted That Met QC Criteria

April 26, 2021

First Posted (Actual)

April 29, 2021

Study Record Updates

Last Update Posted (Actual)

July 25, 2023

Last Update Submitted That Met QC Criteria

July 24, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on Exposure to culture media

3
Subscribe